Several in vitro and in vivo studies on mouse models, aimed to investigate the anti-cancer effect of sPD-1, demonstrated that sPD-1 blockade of PD-L1 could increase activation and cytotoxicity of T cells as well as promote reduction of tumor growth (24–27). Here, HOXD13 is linked to cancer.